Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment


- Data are...

Related Keywords

Delaware ,United States ,San Diego ,California ,American ,Michaela Metzger ,Daniel Wolff ,Pabloj Cagnoni ,Kaplan Meier ,Company On Twitter ,Linkedin ,Development Incyte ,Exchange Commission ,American Society Of Hematology Annual Meeting ,Professor At University Hospital Regensburg ,Drug Administration ,Syndax Pharmaceuticals ,Syndax Pharmaceuticals Nasdaq ,Head Of Research ,Plenary Scientific Session ,American Society ,Hematology Annual Meeting ,Lee Symptom Scale ,Chief Executive Officer ,Senior Physician ,University Hospital ,Biologics License Application ,Orphan Drug Designation ,Modified Lee Symptom ,Private Securities Litigation Reform Act ,Immunology Insights ,Real World Treatment ,Markets ,